- Home
- ACON vs GLTO Comparison
ACON vs GLTO Comparison
Compare ACON & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- GLTO
- Stock Information
- Founded
- ACON 2008
- GLTO 2011
- Country
- ACON United States
- GLTO Denmark
- Employees
- ACON N/A
- GLTO N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- GLTO Health Care
- Exchange
- ACON Nasdaq
- GLTO Nasdaq
- Market Cap
- ACON 4.2M
- GLTO 4.4M
- IPO Year
- ACON 2022
- GLTO 2020
- Fundamental
- Price
- ACON $7.28
- GLTO $3.35
- Analyst Decision
- ACON Buy
- GLTO Buy
- Analyst Count
- ACON 2
- GLTO 1
- Target Price
- ACON $481.00
- GLTO $10.00
- AVG Volume (30 Days)
- ACON 15.5K
- GLTO 18.8K
- Earning Date
- ACON 08-13-2025
- GLTO 08-11-2025
- Dividend Yield
- ACON N/A
- GLTO N/A
- EPS Growth
- ACON N/A
- GLTO N/A
- EPS
- ACON N/A
- GLTO N/A
- Revenue
- ACON $54,601.00
- GLTO N/A
- Revenue This Year
- ACON $212.31
- GLTO N/A
- Revenue Next Year
- ACON $92.86
- GLTO N/A
- P/E Ratio
- ACON N/A
- GLTO N/A
- Revenue Growth
- ACON N/A
- GLTO N/A
- 52 Week Low
- ACON $6.20
- GLTO $2.01
- 52 Week High
- ACON $3,499.51
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- ACON 42.96
- GLTO 65.19
- Support Level
- ACON $6.79
- GLTO $3.19
- Resistance Level
- ACON $7.29
- GLTO $3.63
- Average True Range (ATR)
- ACON 0.37
- GLTO 0.24
- MACD
- ACON 0.31
- GLTO 0.01
- Stochastic Oscillator
- ACON 45.79
- GLTO 79.37
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.